Skip to main content

Table 1 Inclusion and exclusion criteria for the selection of randomized controlled trials

From: Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

Inclusion criteria
• Adult patients (≥ 18 years of age) diagnosed with HBeAg-positive and/or HBeAg-negative chronic hepatitis B infection
• Treatment of interest: adefovir (ADV), entecavir (ETV), lamivudine (LAM), pegylated interferon (PEG-IFN), telbivudine (TBV), tenofovir alafenamide (TAF) , tenofovir disoproxil fumarate (TDF); as monotherapy or as combination therapy
• Comparators: treatment of interest versus placebo (PLA) or Treatment of interest versus different Treatment of interest
• Outcomes (Efficacy):
 1. Virologic response (VR)
 2. Alanine aminotransferase normalization (ALT norm)
 3. HBeAg loss
 4. HBeAg seroconversion
 5. HBsAg loss
• Study design: published, randomized, controlled interventional studies
Exclusion criteria
• Studies that did not meet the aforementioned selection criteria, uncontrolled non-randomized studies, qualitative studies, observational studies, duplicate publications, conference abstracts, narrative reviews, and editorials were excluded
• Studies not conducted in English
• Studies on special populations: coinfections with HIV or other forms of hepatitis, decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, and pregnancy
• Treatment duration shorter than 48 weeks (except for Interferon therapy)
• Treatment experienced population > 50%
  1. HBeAg hepatitis B e-antigen, HBsAg hepatitis B s-antigen